63,343 Shares in Avalo Therapeutics, Inc. $AVTX Purchased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new stake in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the fourth quarter, Holdings Channel.com reports. The fund purchased 63,343 shares of the company’s stock, valued at approximately $1,150,000. Avalo Therapeutics accounts for approximately 0.9% of Seven Fleet Capital Management LP’s portfolio, making the stock its 20th largest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. UBS Group AG raised its stake in shares of Avalo Therapeutics by 956.9% during the fourth quarter. UBS Group AG now owns 477,816 shares of the company’s stock worth $8,677,000 after buying an additional 432,608 shares during the last quarter. Patient Square Capital LP bought a new position in Avalo Therapeutics in the third quarter valued at approximately $1,271,000. Moody Aldrich Partners LLC bought a new position in Avalo Therapeutics in the fourth quarter valued at approximately $2,419,000. Cantor Fitzgerald L. P. acquired a new stake in Avalo Therapeutics during the 3rd quarter worth $1,083,000. Finally, Nan Fung Trinity HK Ltd. acquired a new stake in Avalo Therapeutics during the 4th quarter worth $3,432,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AVTX. Wedbush cut their price target on Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a report on Wednesday, May 6th. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Citizens Jmp reduced their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Finally, Piper Sandler reissued an “overweight” rating and issued a $60.00 target price (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.67.

Avalo Therapeutics Price Performance

NASDAQ:AVTX opened at $14.70 on Friday. The company has a market cap of $772.78 million, a P/E ratio of -2.69 and a beta of 0.83. Avalo Therapeutics, Inc. has a one year low of $4.50 and a one year high of $24.27. The firm’s fifty day moving average price is $15.51 and its two-hundred day moving average price is $16.09.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.02. As a group, equities research analysts expect that Avalo Therapeutics, Inc. will post -2.58 earnings per share for the current year.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Paul Varki sold 75,063 shares of Avalo Therapeutics stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total value of $1,514,020.71. Following the transaction, the insider owned 3,634 shares in the company, valued at $73,297.78. The trade was a 95.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 3,970 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.01, for a total transaction of $71,499.70. Following the completion of the transaction, the insider directly owned 3,622 shares of the company’s stock, valued at $65,232.22. This trade represents a 52.29% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 112,586 shares of company stock worth $2,089,651 in the last 90 days. Company insiders own 4.46% of the company’s stock.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.